Published in J Biol Chem on October 02, 2003
Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest (2003) 2.51
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis (2006) 2.18
Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology (2015) 1.65
Steatohepatitis in laboratory opossums exhibiting a high lipemic response to dietary cholesterol and fat. Am J Physiol Gastrointest Liver Physiol (2012) 1.59
Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch (2006) 1.43
FXR signaling in the enterohepatic system. Mol Cell Endocrinol (2012) 1.32
Bile formation and secretion. Compr Physiol (2013) 1.32
Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol (2012) 1.30
Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci U S A (2006) 1.27
Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis. J Clin Invest (2010) 1.17
Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. Hepatology (2013) 1.13
Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity. Mol Endocrinol (2010) 1.11
Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS One (2009) 1.08
FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol (2011) 1.08
Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol (2009) 1.07
Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun (2016) 1.05
New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J Hepatol (2006) 1.03
Impact of bile acids on the growth of human cholangiocarcinoma via FXR. J Hematol Oncol (2011) 1.03
Endocrine and paracrine role of bile acids. World J Gastroenterol (2008) 1.02
Transcriptome analysis of salt tolerant common bean (Phaseolus vulgaris L.) under saline conditions. PLoS One (2014) 0.94
Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis (2013) 0.91
Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes. PLoS One (2014) 0.89
Fibrates and cholestasis. Hepatology (2015) 0.86
Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes. Int J Endocrinol (2014) 0.84
The Multiple Facets of ABCB4 (MDR3) Deficiency. Curr Treat Options Gastroenterol (2007) 0.80
Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opin Pharmacother (2014) 0.78
Swertianlarin, an Herbal Agent Derived from Swertia mussotii Franch, Attenuates Liver Injury, Inflammation, and Cholestasis in Common Bile Duct-Ligated Rats. Evid Based Complement Alternat Med (2015) 0.76
Hepatobiliary transport in health and disease. Clin Lipidol (2012) 0.76
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature (2010) 10.60
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet (2007) 6.57
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet (2010) 6.49
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation (2008) 5.20
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol (2003) 5.04
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet (2009) 4.63
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet (2013) 3.87
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med (2004) 3.34
Mapping of a major locus that determines telomere length in humans. Am J Hum Genet (2004) 3.33
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Common variants near TERC are associated with mean telomere length. Nat Genet (2010) 2.98
Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol (2008) 2.48
Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat Biotechnol (2011) 2.37
Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med (2010) 2.13
Bivariate random-effects meta-analysis and the estimation of between-study correlation. BMC Med Res Methodol (2007) 2.13
Biostatistical aspects of genome-wide association studies. Biom J (2008) 2.13
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med (2005) 2.12
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J (2004) 1.99
(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem (2005) 1.99
Serious complications of local anaesthesia for cataract surgery: a 1 year national survey in the United Kingdom. Br J Ophthalmol (2006) 1.96
Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol (2004) 1.94
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem (2007) 1.92
The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol (2005) 1.88
Re: Estimation of bias in nongenetic observational studies using "Mendelian triangulation" by Bautista et al. Ann Epidemiol (2007) 1.86
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown. Biostatistics (2007) 1.74
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation (2002) 1.72
Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med (2012) 1.71
Dendritic mRNAs encode diversified functionalities in hippocampal pyramidal neurons. BMC Neurosci (2006) 1.66
A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet (2011) 1.63
Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet (2011) 1.60
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res (2009) 1.54
A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry (2012) 1.52
Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke (2013) 1.51
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics (2010) 1.50
Adjusting for bias and unmeasured confounding in Mendelian randomization studies with binary responses. Int J Epidemiol (2008) 1.45
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A (2006) 1.44
A regulatory SNP of the BICD1 gene contributes to telomere length variation in humans. Hum Mol Genet (2008) 1.43
The prevalence of nystagmus: the Leicestershire nystagmus survey. Invest Ophthalmol Vis Sci (2009) 1.35
The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J Biol Chem (2003) 1.35
Evidence-based sample size calculations based upon updated meta-analysis. Stat Med (2007) 1.35
Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem (2003) 1.33
Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics (2006) 1.27
An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. Am J Epidemiol (2004) 1.26
Methods for meta-analyses of genome-wide association studies: critical assessment of empirical evidence. Am J Epidemiol (2012) 1.24
Genetic architecture of ambulatory blood pressure in the general population: insights from cardiovascular gene-centric array. Hypertension (2010) 1.22
Molecular characterization of the murine SIGNR1 gene encoding a C-type lectin homologous to human DC-SIGN and DC-SIGNR. Gene (2002) 1.19
The VF-14 and psychological impact of amblyopia and strabismus. Invest Ophthalmol Vis Sci (2006) 1.19
Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS Med (2013) 1.18
How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol (2007) 1.17
Nicotinic acid receptor agonists differentially activate downstream effectors. J Biol Chem (2007) 1.16
Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem Biophys Res Commun (2008) 1.16
Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol (2004) 1.16
DWE: discriminating word enumerator. Bioinformatics (2004) 1.15
A generalized weighting regression-derived meta-analysis estimator robust to small-study effects and heterogeneity. Stat Med (2012) 1.14
Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem (2002) 1.14
A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem (2002) 1.13
Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype. Biochem Pharmacol (2005) 1.13
Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol (2013) 1.09
Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers. Arch Gen Psychiatry (2012) 1.08
Meta-analysis of diagnostic test studies using individual patient data and aggregate data. Stat Med (2008) 1.07
Bayesian implementation of a genetic model-free approach to the meta-analysis of genetic association studies. Stat Med (2005) 1.07
Factors associated with success in first-time trabeculectomy for patients at low risk of failure with chronic open-angle glaucoma. Ophthalmology (2004) 1.06
Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol (2013) 1.05
Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res (2011) 1.05
The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J Am Coll Cardiol (2004) 1.05
Multivariate meta-analysis of mixed outcomes: a Bayesian approach. Stat Med (2013) 1.05
Commentary: development of Mendelian randomization: from hypothesis test to 'Mendelian deconfounding'. Int J Epidemiol (2004) 1.04
Functional analysis of sites within PCSK9 responsible for hypercholesterolemia. J Lipid Res (2008) 1.03